Partial dopamine agonists and the treatment of psychosis

Current Neuropharmacology

Volumn 3, Issue 1, 2005, Pages 3-8

  Tamminga, Carol A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

( ) 3PPP aripiprazole; Affinity; Apomorphine; Intrinsic activity; N propyl noraporphine

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; BROMOCRIPTINE; CF 25397; CHLORPROMAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PRECLAMOL; PROPYLNORAPOMORPHINE; RISPERIDONE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CLINICAL TRIAL; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; MOTOR DYSFUNCTION; NEUROTRANSMISSION; NONHUMAN; PSYCHOSIS; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA;

EID: 13844297403     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159052773404     Document Type: Review

References (41)

1. Aghajanian, G.K., Bunney, B.S. (1973) Central dopaminergic neurons: Neurophysiologic identification and responses to drugs. In: Usdin, E., Snyder, S., eds. Frontiers in Catecholmine Research. New York: Pergamon Press, 643-645.
2. Ariens, E.J. (1983) Intrinsic activity: partial agonists and partial antagonists. J. Cardiovasc. Pharmacol., 5 Suppl. 1, S8-15.
3. Astrachan, B.M., Harrow, M., Adler, D., Silbersweig, D., Stem, E. (1972) A checklist for the diagnosis of schizophrenia. Br. J. Psychiatry., 121, 529-539.
4. Bunney, B.S., Aghajanian, G.K., Roth, R.H. (1973) Comparison of effects of L-dopa, amphetamine, and apomorphine on firing rate of rat dopaminergic neurons. Nature, 245, 123-125.
5. Burris, K.D., Molski, T.F., Xu, C., Heckers, S., Rauch, S.L., Goff, D., Savage, C.R., Schacter, D.L.F.A., Alpert, N.M. (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther., 302 381-390.
6. Carlsson, A. (1975) Receptor Mediated Control of Dopamine Metabolism. In: Usdin, E., Bunney, W.E., eds. Pre-and Postsynaptic Receptors. New York: Marcel Dekker, Inc., 49-65.
7. Carlsson, A. (1983) Dopamine receptor agonists: intrinsic activity vs. state of receptor. J. Neural. Transm., 57, 309-315.
8. Carlsson, A. (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsycho-pharmacology, 1, 179-186.
9. Carlsson, A. Lindquist M. (1963) Effect of chlorpromazine and haloperidol of formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol., 140-144.
10. Clark, D., Hjorth, S., Carlsson, A. (1985) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J. Neural. Transm., 62, 1-52.
11. Clark, D., Hjorth, S., Carlsson, A. (1985)Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J. Neural. Transm., 62, 171-207.
12. Davis, J.M. (1969) Review of antipsychotic drug literature. In: Klein, D.F., Davis, J.M., eds. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: The Williams and Wilkins Company, 52-138.
13. Davis, K.L., Kahn, R.S., Ko, G., Davidson, M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry , 148, 1474-1486.
14. Delay, J., Deniker, P., Harl, J.-M. (1952) Traitement de etats d'excitation et d'agitation par une methode medicamenteuse derivee de l'hibernotherapie. Ann. Med. Psychol., 110, 267-273.
15. Douglas, C.J. (1900) Apomorphine in agitation. N. Y. Med. 71, 376.
16. Farnebo, L.O., Hamberger, B. (1971) Drug-induced changes in the release of 3 H-monoamines from field stimulated rat brain slices. Acta Physiol. Scand. Suppl., 371, 35-44.
17. Feldman, F., Susselman, S., Barrera, S.E. (1945) Apomorphine treatment of war psychosis. Am. J. Psychiatry., 102, 403.
18. Ferrier, E.C. (1984) Clinical effects of apomorphine in schizophrenia. Br. J. Psychiatry., 144, 341-348.
19. Fujikawa, M., Nagashima, M., Inoue, T., Yamada, K., Furukawa, T. (1996) Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol. Biochem. Behav., 53, 903-909.
20. Green, M.F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry., 153, 321-330.
21. Inoue, T., Domae, M., Yamada, K., Furukawa, T. (1996) Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-l -piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther., 277, 137-143.
22. Jordan, S., Koprivica, V., Chen, R., Klein, D.F., Davis, J.M. (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol., 441, 137-140.
23. Kehr, W., Carlsson, A., Lindqvist, M., Magnusson, T., Atack, C. (1972) Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmacol., 24, 744-747.
24. Kenakin, T.P. (1993) Pharmacologic Analysis of Drug-receptor Interaction. New York, NY: Raven Press.
25. Krogsgaard-Larsen, P. (1994) Glutamic acid and schizophrenia: potential pharmacological and therapeutic approaches. In: Fog, R., Gerlach, J., Hemmingsen, R., eds. Schizophrenia: An Integrated View. Copenhagen, Denmark: Munksgaard Press, 379-398.
26. Lahti, A.C., Weiler, M.A., Corey, P.K., Sunahara, R.K., Niznik, H.B., Weiner, D.M., Stormann, T.M., Brann, M.R., Kennedy, J.L., Gelernter, J.E., Rozmahel, R., Yang, Y.L., Israel, Y. (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperi-dine(preclamol) in schizophrenia. Biol. Psychiatry., 43, 2-11.
27. Lahti, R.A., Lahti, A.C., Tamminga, C.A. (1995) D2-Family Receptors in Schizophrenia: Distribution and Implications for Treatment. Clin. Neuropharmacol., 18, S110-S120.
28. Langer, S.Z. (1980) Presynaptic regulation of the release of catecholamines. Pharmacol. Rev., 32, 337-362.
29. Levy, M.I. (1984) Apomorphine and schizophrenia: Treatment, CSF, and neuroendocrine responses. Arch. Gen. Psychiatry., 41 520-524.
30. Marder, S.R, McQuade, R.D, Stock, E., Monsma, F.J. Jr., Mahan, L.C., McVittie, L.D., Gerfen, C.R., Sibley, D.R. (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res., 61 123-136.
31. Potkin, S.G., Saha, A., Kujawa, M.J., Sunahara, R.K., Guan, H.C., O'Dowd, B.F., Seeman, P., Laurier, L.G., Ng, G., George, S.R., Torchia, J., Van Tol, H.H., Niznik, H.B. (2003) Aripiprazole, an antipsychotic with a novel mechanism of action and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry., 60, 681-690.
32. Smith, R.C., Tamminga, C., Davis, J.M. (1977) Effect of apomorphine on schizophrenic symptoms. J. Neural. Transm., 40 171-176.
33. Tamminga, C.A. (1994) Development in somatic treatments: Introduction. Am. J. Psychiatry., 151, 216-219.
34. Tamminga, C.A. (1998) Principles of the pharmacotherapy of schizophrenia. In: Bunney, B.S., ed. Neurobiology of Psychiatric Disorders. New York: Oxford University Press, 272-285.
35. Tamminga, C.A., Cascella, N.G., Lahti, R.A., Lindberg, M., Carlsson, A. (1992) Pharmacologic properties of (-)-3PPP (preclamol) in man. J. Neural. Transm. Gen. Sect., 88, 165-175.
36. Tamminga, C.A., Crayton, J.W., Chase, T.N. (1979) Improvement in tardive dyskinesia after muscimol therapy. Arch. Gen. Psychiatry , 36, 595-598.
37. Tamminga, C.A., Gotts, M.D., Thaker, G.K., Alphs, L.D., Foster, N.L. (1986) Dopamine agonist treatment of schizophrenia with N- propylnorapomorphine [published erraturn appears in Arch. Gen. Psychiatry. 1986 Sep, 43(9), 899]. Arch. Gen. Psychiatry., 43, 398-402.
38. Tamminga, C.A, Schaffer, M.H. (1979) Treatment of Schizophrenia with ergot derivatives. Psychopharmacology, 66, 239-242.
39. Tamminga, C.A., Schaffer, M.H., Smith, R.C., Davis,J.M. (1978) Schizophrenic symptoms improve with apomorphine. Science, 200, 567-568.
40. Walinder, J., Skott, A., Carlsson, A., Roos, B.E. (1976) Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique. Arch. Gen. Psychiatry., 33, 501-505.
41. Walters, J.R., Bunney, B.S., Roth, R.H. (1975) Piribedil and apomorphine: pre- and postsynaptic effects on dopamine synthesis and neuronal activity. Adv. Neurol., 9, 273-284.